SANTA CLARA, Calif.--(BUSINESS WIRE)--Today, Affymetrix, Inc. (Nasdaq: AFFX) launched its next-generation series of products for cytogenetics. The entirely new solution, which includes arrays, reagents, and software, enables fast and reliable detection of known and novel chromosome aberrations.
